Tackling High Costs Of Developing AAV-Based Therapeutics

Many gene therapies rely on modified adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes directly to target cells, which offers promising solutions for a wide range of genetic disorders. However, the development process often faces challenges in accurately resolving monomers from dimers across various AAV serotypes, which can impact both efficacy and safety. A cutting-edge solution now addresses this issue by significantly improving resolution while reducing sample consumption by up to 90% compared to traditional size-exclusion chromatography (SEC) columns. This advancement not only accelerates the development timeline but also substantially lowers production costs, making gene therapy more accessible and scalable.

Discover how this innovative approach can streamline your process and enhance your therapeutic pipeline.